Co-Diagnostics 年会未达法定人数并延期召开

----- form8-k.htm -----
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported):
September 3, 2026
CO-DIAGNOSTICS,
INC.
(Exact
name of registrant as specified in its charter)
Utah
001-38148
46-2609363
(State
or other jurisdiction
of
incorporation)
(Commission
File Number)
(IRS
Employer
Identification
No. )
2401
S. Foothill Drive
,
Suite D
,
Salt Lake City
Utah
84109
(Address
of principal executive offices) (Zip Code)
(801)
438-1036
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
Common
Stock, par value $0.001 per share
CODX
The
Nasdaq
Capital Market
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.07. Submission of Matters to a Vote of Security Holders.
On
September 3, 2026, Co-Diagnostics, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders
(the “Annual Meeting”). However, the Company did not achieve a quorum and therefore was unable to transact business at the
meeting.
Pursuant
to the Company’s bylaws, if a quorum is not present or represented at any meeting of the stockholders, the chairperson of the meeting
has the power to adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum is present
or represented. Accordingly, the Annual Meeting was adjourned to September 24, 2026, at 9:00 a.m. Mountain Time. The adjourned meeting
will be held at the Company’s offices located at 2401 S. Foothill Dr, Ste. D, Salt Lake City, Utah 84109.
At
the adjourned Annual Meeting on September 24, 2026, stockholders will be deemed to be present in person and vote at such adjourned meeting
in the same manner as disclosed in the definitive proxy statement the Company filed with the Securities and Exchange Commission on July
21, 2026. Valid proxies submitted prior to the reconvened Annual Meeting will continue to be valid for the upcoming reconvened Annual
Meeting, unless properly changed or revoked prior to votes being taken at such reconvened Annual Meeting.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
CO-DIAGNOSTICS,
INC.
Date:
September 4, 2026
By:
/s/
Dwight Egan
Name:
Dwight
Egan
Title:
Chief
Executive Officer
(Principal
Executive Officer)